Hikma: API facility bolsters our oncology pipeline

By Dan Stanton

- Last updated on GMT

Hikma: API facility bolsters our oncology pipeline

Related tags Pharmaceutical drug

Hikma has opened a new API facility in Jordan to support its oncology pipeline.

The new facility is located in Amman, Jordan and is an extension to an existing active pharmaceutical ingredient (API) site, adjacent to the company’s headquarters.

The site was inaugurated last week by King Abdallah of Jordan and will produce the raw materials for Hikma’s pipeline.

“Currently we’ve 5 oncology APIs in the development pipelines,”​ Hikma spokesman Ben Atwell was able to tell in-Pharmatechnologist.com, though he did not reveal more information about the new site or how it would support Hikma’s API network.

In 2011​, the firm invested $33m (€23m) in a joint venture with Indian API and intermediate firm Unimark Remedies in order to develop specialised APIs.

Recently the firm has been focusing on the sterile injectables market, having rebuffed offers to sell its ‘lucrative’ business last year to Amgen and Novartis​, and buying Ohio-based Bedford Labs​ – and subsequently troubled manufacturer Ben Venue Labs - for $300m in May.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...